The situation was studied, and our findings suggest that for COVID-19-affected patients undergoing chemotherapy for lung cancer, a history of ICI within 90 days and elevated CRP level (≥ 2.75 mg/dL) were found to be potential factors leading to respiratory failure. This evidence concerns the gene CRP and COVID-19.